Advanced in Richter Syndrome

Dr. Rajat Bannerji

Hematology Oncology | Oncology
195 Little Albany St, 
New Brunswick, NJ 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Richter Syndrome
195 Little Albany St, 
New Brunswick, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajat Bannerji is a Hematologist Oncology specialist and an Oncologist in New Brunswick, New Jersey. Dr. Bannerji is rated as an Advanced provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

195 Little Albany St, New Brunswick, NJ 08901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
BrUOG 401: A Phase 2 Study of Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Enrollment Status: Recruiting
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drugs: Mosunetuzumab, Lenalidomide
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Enrollment Status: Completed
Publish Date: May 19, 2022
Intervention Type: Drug
Study Drug: TRPH-222
Study Phase: Phase 1
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Active_not_recruiting
Publish Date: January 19, 2021
Intervention Type: Drug
Study Drugs: Romidepsin, Ixazomib
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Rituximab, Venetoclax (ABT 199) and Bortezomib in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2 Study of Rituximab, Venetoclax (ABT 199) and Bortezomib in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Withdrawn
Publish Date: June 16, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

24 Total Publications

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies.
Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies.
Journal: Clinical pharmacology in drug development
Published: January 13, 2025
Similar Doctors
Elite in Richter Syndrome
Dr. John N. Allan
Hematology Oncology | Oncology | Hematology
Elite in Richter Syndrome
Dr. John N. Allan
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

520 E 70th St, 
New York, NY 
 (31.9 miles away)
646-962-2012
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Allan is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Allan has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Splenectomy.

Richard R. Furman
Elite in Richter Syndrome
Dr. Richard R. Furman
Hematology | Oncology
Elite in Richter Syndrome
Dr. Richard R. Furman
Hematology | Oncology

Weill Medical College Of Cornell

520 E 70th St, Suite 651, 
New York, NY 
 (31.9 miles away)
212-746-6575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Furman is a Hematologist and an Oncologist in New York, New York. Dr. Furman is rated as an Elite provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Lymphadenectomy.

Distinguished in Richter Syndrome
Dr. Kanti R. Rai
Hematology Oncology | Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Kanti R. Rai
Hematology Oncology | Hematology | Oncology

North Shore Health System Medical Faculty Group Practice Inc

410 Lakeville Rd, Suite 212, 
New Hyde Park, NY 
 (42.9 miles away)
516-470-4050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kanti Rai is a Hematologist Oncology specialist and a Hematologist in New Hyde Park, New York. Dr. Rai is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, and Richter Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bannerji's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 31 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile